Quanterix Corp
QTRX
查看詳細走勢圖
6.800USD
+0.210+3.19%
收盤 12/22, 16:00（美東）報價延遲15分鐘
317.44M總市值
虧損本益比TTM
盤中分時
1分
30分
1小時
日k
週k
月k
日k
今天
+3.19%
5天
-8.23%
1月
+2.10%
6月
+11.11%
今年開始到現在
-36.03%
1年
-35.24%
查看詳細走勢圖
TradingKey Quanterix Corp股票評分
單位: USD 更新時間: 2025-12-22操作建議
Quanterix Corp當前公司基本面數據相對健康，增長潛力很大。當前估值合理，在醫療設備與耗材行業排名104/208位。機構持股佔比非常高，近一個月多位分析師給出公司評級為持有。最高目標價6.50。中期看，股價處於上升通道。近一個月，市場表現一般，但基本面評分較高。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Quanterix Corp評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
4
分析師
持有
評級
6.500
目標均價
-13.91%
漲幅空間
數據免責聲明：分析師評級與目標價由LSEG提供，僅供參考，不應當作投資建議
Quanterix Corp亮點
亮點風險
Quanterix Corporation is engaged in fueling scientific discovery through ultra-sensitive biomarker detection. The Company’s Simoa technology delivers earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the level of quantification (LoQ). Its precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Its products and services include Simoa Assay Kits, Simoa Dry Blood Extraction Kit, LDTs & Assay Services, Instruments, Simoa Accelerator Laboratory, Homebrew-Custom Assay Development, and Nova Beads. LDTs & Assay Services include Simoa p-Tau 217, Simoa NfL LDT, and LucentAD pTau 217. Its instruments include Simoa HD-X Analyzer-Automated Immunoassays, Quanterix SR-X Biomarker Detection System, and SP-X Imaging and Analysis System.
業績高增長
公司營業收入穩步增長，連續3年增長30.23%
估值高估
公司最新PE估值-2.91，處於3年歷史高位
機構減倉
最新機構持股34.11M股，環比減少21.83%
PRFDX持倉
明星投資者PRFDX持倉，最新持倉19.04K股
Quanterix Corp新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Quanterix Corp簡介
Quanterix Corporation is engaged in fueling scientific discovery through ultra-sensitive biomarker detection. The Company’s Simoa technology delivers earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the level of quantification (LoQ). Its precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Its products and services include Simoa Assay Kits, Simoa Dry Blood Extraction Kit, LDTs & Assay Services, Instruments, Simoa Accelerator Laboratory, Homebrew-Custom Assay Development, and Nova Beads. LDTs & Assay Services include Simoa p-Tau 217, Simoa NfL LDT, and LucentAD pTau 217. Its instruments include Simoa HD-X Analyzer-Automated Immunoassays, Quanterix SR-X Biomarker Detection System, and SP-X Imaging and Analysis System.
公司代碼QTRX
公司Quanterix Corp
CEOToloue (Masoud)
網址https://www.quanterix.com/
常見問題
Quanterix Corp(QTRX)的當前股價是多少？
Quanterix Corp(QTRX)的當前股價是 6.800。
Quanterix Corp 的股票代碼是什麼？
Quanterix Corp的股票代碼是QTRX。
Quanterix Corp股票的52週最高點是多少？
Quanterix Corp股票的52週最高點是12.406。
Quanterix Corp股票的52週最低點是多少？
Quanterix Corp股票的52週最低點是4.050。
Quanterix Corp的市值是多少？
Quanterix Corp的市值是317.44M。
Quanterix Corp的淨利潤是多少？
Quanterix Corp的淨利潤為-38.53M。
現在Quanterix Corp(QTRX)的股票是買入、持有還是賣出？
根據分析師評級，Quanterix Corp(QTRX)的總體評級為持有，目標價格為6.500。
Quanterix Corp(QTRX)股票的每股收益（EPS TTM）是多少
Quanterix Corp(QTRX)股票的每股收益（EPS TTM）是-2.339。
相關品種
-0.68%
-0.20%
+1.37%
+1.29%
+1.43%
+0.86%
+0.35%
-0.93%
-0.19%
+0.78%
+1.07%
+1.35%
-0.31%
+0.25%
+0.59%
+0.99%
+0.74%
+0.93%
+1.27%
+0.65%
